Meeting
2016 ASCO Annual Meeting
Optimal endocrine therapy for breast cancer patients 45-50 years of age at diagnosis.
Authors
Gwen Dackus
Division of Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital, Amsterdam, Netherlands
Gwen Dackus , Katarzyna Józwiak , Gabe S. Sonke , Elsken Van Der Wall , Paul J. van Diest , Sabine Siesling , Michael Hauptmann , Sabine C. Linn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 34, 2016 (suppl; abstr 551)
DOI
10.1200/JCO.2016.34.15_suppl.551
Abstract #
551
Poster Bd #
39
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.
First Author: Maria Vittoria Dieci
Poster
2018 ASCO Annual Meeting
Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis.
First Author: Sara A. Hurvitz
Poster
2023 ASCO Annual Meeting
A randomized phase 2 non-inferiority trial of (Z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE).
First Author: Matthew P. Goetz
Poster
2023 ASCO Annual Meeting
Efficacy of ovarian function suppression of 3-monthly versus monthly GnRH agonist as endocrine therapy for premenopausal breast cancer patients.
First Author: Daniella Audi Blotta